[1]XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants[J].Chin Med J(Engl),2022,135(5):584-590.
[2]HE T,GAO Y,FANG Y,et al.The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer[J].Cancer Biol Med,2022,19(8):1172-1192.
[3]HICKS KC,KNUDSON KM,LEE KL,et al.Cooperative immune-mediated mechanisms of the HDAC inhibitor entinostat,an IL15 superagonist,and a cancer vaccine effectively synergize as a novel cancer therapy[J].Clin Cancer Res,2020,26(3):704-716.
[4]SHIN HS,CHOI J,LEE J,et al.Histone deacetylase as a valuable predictive biomarker and therapeutic target in immunotherapy for non-small cell lung cancer[J].Cancer Res Treat,2022,54(2):458-468.
[5]VENUGOPAL B,BAIRD R,KRISTELEIT RS,et al.A phase I study of quisinostat(JNJ-26481585),an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity,in patients with advanced solid tumors[J].Clin Cancer Res,2013,19(15):4262-4272.
[6]SHINDO Y,ARAI W,KONNO T,et al.Effects of histone deacetylase inhibitors tricostatin A and quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells[J].Histochem Cell Biol,2021,155(6):637-653.
[7]FUKUDA K,TAKEUCHI S,ARAI S,et al.Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer[J].Cancer Sci,2020,111(7):2374-2384.
[8]MOREAU P,FACON T,TOUZEAU C,et al.Quisinostat,bortezomib,and dexamethasone combination therapy for relapsed multiple myeloma[J].Leukemia & Lymphoma,2016,57(7):1546-1559.
[9]CHEN CT,SALUNKE S,WEI TT,et al.Fluorescent nanohybrids from ZnS/CdSe quantum dots functionalized with triantennary,N-Hydroxy-P-(4-arylbutanamido)benzamide/gallamide dendrons that act as inhibitors of histone deacetylase for lung cancer[J].ACS APPl Bio Mater,2021,4(3):2475-2489.
[10]MAMDANI H,JALAL SI.Histone deacetylase inhibition in non-small cell lung cancer:hype or hope[J].Front Cell Dev Biol,2020,8(1):582370-582379.
[11]HERNANDEZ-ROSAS F,HERNANDEZ-OLIVERAS A,FLORES-PEREDO L,et al.Histone deacetylase inhibitors induce the expression of tumor suppressor genes per1 and per2 in human gastric cancer cells[J].Oncol Lett,2018,16(2):1981-1990.
[12]HE B,DAI L,ZHANG X,et al.The HDAC inhibitor quisinostat(JNJ-26481585) supresses hepatocellular carcinoma alone and synergistically in combination with sorafenib by G0/G1 phase arrest and apoptosis induction[J].Int J Biol Sci,2018,14(13):1845-1858.
[13]BAO LM,DIAO H,DONG N,et al.Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation[J].Cell Biol Toxicol,2016,32(6):469-482.
[14]LI F,WANG T,WANG Z,et al.Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HEPG2 cells[J].Mol Med Rep,2017,16(5):6094-6101.
[15]HEINICKE U,HAYDN T,KEHR S,et al.BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis[J].Oncogene,2018,37(39):5325-5339.
[16]ENBLE JC,BOEDICKER C,WANIOR M,et al.Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells[J].Cancer Lett,2018,428(1):160-172.
[17]HEINICKE U,KUPKA J,FICHTER I,et al.Critical role of mitochondria-mediated apoptosis for JNJ-26481585 induced antitumor activity in rhabdomyosarcoma[J].Oncogene,2016,35(28):3729-3741.
[18]ZHANG MY,WANG JP.A multi-target protein of hTERTR-FAM96A presents significant anticancer potent in the treatment of hepatocellular carcinoma[J].Tumour Biol,2017,39(4):101042831769834.
[19]SCHWAMB B,PICK R,FERNNDEZ SB,et al.FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors[J].Int J Cancer,2015,137(6):1318-1329.
[20]WANG WP,GAO HY.Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity[J].Exp Ther Med,2018,15(1):641-648.
[21]CHIDAMBARAM A,SUNDARARAJU K,CHIDAMBARAM RK,et al.Design,synthesis,and characterization of α,β-unsaturated carboxylic acid,and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line[J].J Cell Physiol,2018,233(7):5293-5309.
[22]MORALES TORRES C,WU MY,HOBOR S,et al.Selective inhibition of cancer cell self-renewal through a quisinostat-histone H1.0 axis[J].Nat Commun,2020,11(1):1792-1806.